Tüdőrák: ki dolgozik rajta

Intézményenként egy kártya. Célpontra vagy országra szűkítheted a listát.

• Minden célpont
• EGFR 301
• PD-L1 162
• PD-1 156
• KRAS 98
• ALK 72
• TP53 10
• HER2 63
• MET 43
• PI3K 1
• STAT3 0
• AKT 2
• ROS1 27
• VEGF 23
• mTOR 0
• BRAF 9
• RET 9
• NRF2 1
• MAPK 1
• ERK 0
• STING 0
• STK11 7
• YAP 1
• DLL3 27
• CTLA-4 15
• TROP2 14
• CTNNB1 0
• RAS 15
• JAK 1
• HIF-1 1
• AMPK 0
• PARP 2
• KEAP1 5
• JNK 0
• MYC 1
• B7-H3 14
• GPX4 0
• HER3 11
• PTEN 4
• MEK 1
• TIGIT 6
• FGFR 3
• IL-6 1
• PPAR 0
• EZH2 2
• HDAC 0
• PRMT5 7
• FAK 0
• COX-2 0
• HMGB1 0
• NTRK 5
• AXL 3
• BCL-2 0
• CDK4/6 4
• CXCR4 1
• CD47 1
• METTL3 0
• NLRP3 0
• SHP2 0
• HSP90 0
• MDM2 1

64+ intézményből 24, a friss publikációk és a nyitott vizsgálatok szerint rendezve. Ez nem minőségi rangsor.

Funded research projects that name this disease in their title, terms or summary and have not ended yet: who is funded, where, how much and until when. Organisations only; the funder's page has the details.

• U.S. Department of Veterans Affairs · IK6

  ISRM Research Career Scientist Award Application

  Veterans Health Administration· Pittsburgh, Egyesült Államok· until 2031. szept.

• NIH NIEHS · F31

  PhosFate: Investigating Chemical Hazards, Community Exposures, and Health Risks from Phosphate Fertilizer Manufacturing

  University of South Florida· Tampa, Egyesült Államok· 41 102 USD awarded in fiscal year 2026· until 2028. szept.

• NIH NIDCR · F32

  Transposon derived neo-antigens in NSD1 mutant Head and Neck Cancers

  Columbia University Health Sciences· New York, Egyesült Államok· 77 580 USD awarded in fiscal year 2026· until 2028. szept.

• NIH NCI · R01

  Role of Allostatic Load in Immunotherapy Outcomes

  Ut Southwestern Medical Center· Dallas, Egyesült Államok· 389 844 USD awarded in fiscal year 2026· until 2031. aug.

• NIH NCI · R21

  Tackling tumor recurrence in pediatric brain tumors: identification of epigenetic memory and tumor microenvironment conducive to tumor recurrence in an inducible and reversible H3K27M murine model.

  University of Michigan at Ann Arbor· Ann Arbor, Egyesült Államok· 401 115 USD awarded in fiscal year 2026· until 2028. aug.

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF

  Designing Programmable MOF-nanocomposites for Synergistic, Redox-Driven Antitumor Therapies (Photo-bioMOF)

  Fundacion IMDEA Energia· Mostoles Madrid, Spanyolország· EU contribution 262 393 EUR· until 2030. febr.· 2 countries

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-ERC

  Identifying and disrupting neuroimmune circuits in cancer (NeuroCAN)

  Universitat Basel· Basel, Svájc· EU contribution 1 874 590 EUR· until 2032. jún.

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF

  Predicting immunotherapy response in melanoma and non-small cell lung cancer patients using an extracellular vesicle-derived miRNA signature and a non-invasive CRISPR-based detection assay. (IT-PREDICT)

  Centre Georges-Francois Leclerc Association· Dijon, Franciaország· EU contribution 242 261 EUR· until 2029. márc.

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF

  A Dual Amplification Photoelectrochemical Platform for KRAS Mutation Detection (PEAKRAS)

  Universiteit Antwerpen· Antwerpen, Belgium· EU contribution 216 240 EUR· until 2029. jan.

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-GF

  KRAS Targeting in Oncogenic Systems: reconstructing the KRAS signalling network to identify optimal drug combinations (KRATOS)

  University College Dublin, National University of Ireland, Dublin· Dublin, Írország· EU contribution 426 534 EUR· until 2030. jan.· 2 countries

  The disease is named only in the funder's project summary, not in the title.

10 of 1432 running projects, newest first. Listed amounts together: 828,1 M USD + 224,7 M EUR.

Sources: NIH RePORTER (U.S. National Institutes of Health, public domain) and CORDIS (European Commission, CC BY 4.0). Changes: filtered by disease, organisations matched to ROR.

Leállított, visszavont és felfüggesztett vizsgálatok, a szponzor által a regiszterben megadott okkal, szó szerint idézve.

• Felfüggesztve

  A Study of Poziotinib in Previously Treated Participants With Locally Advanced or Metastatic NSCLC Harboring HER2 Exon 20 Mutations

  NCT05378763· Spectrum Pharmaceuticals, Inc· Frissítve: 2026. okt. 28.

  “The study has not enrolled any patients. The study design is under discussion and will likely be redesigned in consultation with the FDA.”A regiszter szövege, változtatás nélkül. Forrás

• Visszavonták

  A Study of Trastuzumab Deruxtecan in People With Non-Small Cell Lung Cancer

  NCT07428044· Memorial Sloan Kettering Cancer Center· Frissítve: 2026. okt. 20.

  “sponsor closed study”A regiszter szövege, változtatás nélkül. Forrás

• Leállították

  Evaluate BL-M17D1 in Patients w/HER2-Expressing/Mutant Advanced or Metastatic Solid Tumors

  NCT06714617· SystImmune Inc.· Frissítve: 2026. szept. 22.

  “The decision is based only on the Sponsor's internal portfolio prioritization and resource management considerations and is not due to the investigational product's toxicity considerations.”A regiszter szövege, változtatás nélkül. Forrás

• Leállították

  A Study of XMT-2056 in Advanced/Recurrent Solid Tumors That Express HER2

  NCT05514717· Day One Biopharmaceuticals, Inc.· Frissítve: 2026. jún. 18.

  “Development discontinued.”A regiszter szövege, változtatás nélkül. Forrás

• Leállították

  Poziotinib in EGFR Exon 20 Mutant Advanced NSCLC

  NCT03066206· M.D. Anderson Cancer Center· Frissítve: 2026. febr. 20.

  “\<75% participation”A regiszter szövege, változtatás nélkül. Forrás

• Leállították

  A Study of TAS2940 in Participants With Locally Advanced or Metastatic Solid Tumor Cancer

  NCT04982926· Taiho Oncology, Inc.· Frissítve: 2025. okt. 14.

  “After careful review of Taiho's ongoing portfolio and data obtained so far in the context of broader landscape of clinical development in NSCLC HER2mut, Sponsor has made a strategic decision to terminate this study and not based on safety concerns.”A regiszter szövege, változtatás nélkül. Forrás

• Leállították

  A First-in-human Study Using BDC-1001 as a Single Agent and in Combination With Nivolumab in Advanced HER2-Expressing Solid Tumors

  NCT04278144· Bolt Biotherapeutics, Inc.· Frissítve: 2025. szept. 15.

  “Sponsor Decision”A regiszter szövege, változtatás nélkül. Forrás

• Leállították

  DS-8201a in Human Epidermal Growth Factor Receptor 2 (HER2)-Expressing or -Mutated Non-Small Cell Lung Cancer

  NCT03505710· Daiichi Sankyo· Frissítve: 2025. máj. 30.

  “Last participant transitioned to alternative study.”A regiszter szövege, változtatás nélkül. Forrás

Vizsgálatok, amelyek regiszteradata szerint az egyéni résztvevői adatokat (IPD) megosztják.

• An international study evaluating diagnostic and theranostic agents in patients with solid tumors and brain metastases.

  2025-523824-39-01· Medica Scientia Innovation Research S.L.· Forrás

• Real-world Outcome of Zongertinib in Japan (J-HERZ)

  NCT07926308· Boehringer Ingelheim· Forrás

• A Phase 2 Study of Zanidatamab in Patients With HER2-expressing Tumors

  NCT06695845· Jazz Pharmaceuticals· Forrás

• Beamion LUNG-3: Adjuvant Zongertinib vs Standard Treatment in People With Completely Resected Stage II-IIIB NSCLC Harboring Activating HER2 TKD Mutations

  NCT07195695· Boehringer Ingelheim· Forrás

• A Study of Mobocertinib in Japanese Adults With Non-Small Cell Lung Cancer

  NCT03807778· Takeda· Forrás

• A Study of TAK-788 in Adults With Non-Small Cell Lung Cancer

  NCT02716116· Takeda· Forrás

• Study of Trastuzumab Deruxtecan, Pembrolizumab, and Platinum-based Chemotherapy in First-line HER2 Overexpressing Non-small Cell Lung Cancer

  NCT06899126· Daiichi Sankyo· Forrás

• A Study to Investigate the Efficacy and Safety of Trastuzumab Deruxtecan as the First Treatment Option for Unresectable, Locally Advanced/Metastatic Non-Small Cell Lung Cancer With HER2 Mutations

  NCT05048797· AstraZeneca· Forrás

• A Study of Trastuzumab Deruxtecan in People With Non-Small Cell Lung Cancer

  NCT07428044· Memorial Sloan Kettering Cancer Center· Forrás

• Open-Label Study of BBO-10203 in Subjects With Advanced Solid Tumors

  NCT06625775· TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)· Forrás

Publikációk erről a betegségről egy MeSH-módszerkifejezés szerint, például szekvenálási vagy képalkotó módszerre.

• Single-Cell Analysis 145
• Organoids 47
• Mendelian Randomization Analysis 66
• CRISPR-Cas Systems 43
• Gene Expression Profiling 314
• Sequence Analysis, RNA 43
• Whole Genome Sequencing 13
• Exome Sequencing 18
• Proteomics 133
• Metabolomics 67
• Mass Spectrometry 25
• Flow Cytometry 73
• Immunohistochemistry 191
• Liquid Biopsy 76
• Circulating Tumor DNA 83
• Xenograft Model Antitumor Assays 618
• Positron-Emission Tomography 70
• Magnetic Resonance Imaging 116
• Machine Learning 290
• Deep Learning 211
• Cohort Studies 289
• Genome-Wide Association Study 75

• RNA-Adjusted TUFM Protein State Captures Mitochondrial Proteome Organization in Lung Adenocarcinoma.

  J Proteome Res, 2026. nov.

• Midkine drives lung cancer brain metastasis via the NOTCH2/HES1 and PI3K/AKT pathways and serves as a prognostic biomarker.

  Cancer Biomark, 2026. nov.

• Spatial proteomics profiling reveals oncogene-specific immune niches and prognostic markers in non-small cell lung cancer.

  Am J Respir Crit Care Med, 2026. nov.

• Distinct Molecular Pathways Driving Thymic and Pulmonary Neuroendocrine Neoplasms: Organ of Origin Defines Molecular Identity and Yields CD44 as a Marker of Pulmonary Neuroendocrine Tumors.

  Endocr Pathol, 2026. okt.

• Olink Platform-Based Identification of Peripheral Blood Biomarkers for irAEs in Advanced NSCLC.

  Curr Oncol, 2026. okt.

• Integrated multi-omics, network pharmacology, and machine learning reveal the active constituents and pharmacological mechanism of Fufang E'jiao Jiang against lung cancer-related fatigue.

  Anal Chim Acta, 2026. okt.

• A Robust DIA-Based Platform for Large-Scale Plasma Glycoproteomics and Biomarker Discovery.

  J Proteome Res, 2026. okt.

• Peroxiredoxin 6 Silencing Remodels Lipid Metabolism and Redox Pathways to Promote Ferroptosis-Mediated Radiosensitization in Nonsmall Cell Lung Cancer.

  J Proteome Res, 2026. okt.

• Exploratory analysis of extracellular vesicle Profile changes during pembrolizumab treatment in NSCLC.

  Lung Cancer, 2026. szept.

• SpaCEy links spatial tissue patterns to clinical outcomes using explainable graph neural networks.

  Nat Commun, 2026. szept.

Megmutatjuk, a betegség mely célpontjait említi az absztrakt, és onnan a rajtuk dolgozókhoz jutsz.